Three RA patients treated with MTX and TNF inhibitors and 22 with inflammatory bowel disease (IBD) receiving TNF inhibitors had hepatosplenic TCL with a lethal progressive clinical course, as recorded in the database of Food and Drug Administration (FDA) adverse event reporting system [13]. The gene discussed is TNF; the disease is inflammatory bowel disease.